Clinical Response of Severe Mechanobullous Epidermolysis Bullosa Acquisita to Combined Treatment With Immunoadsorption and Rituximab (Anti-CD20 Monoclonal Antibodies) | Zendy

A. Niedermeier | Zendy; Rüdiger Eming | Zendy; Martin Pfütze | Zendy; Christine Neumann | Zendy; Christian Happel | Zendy; Kristian Reich | Zendy; Michael Hertl | Zendy

Open Access

Clinical Response of Severe Mechanobullous Epidermolysis Bullosa Acquisita to Combined Treatment With Immunoadsorption and Rituximab (Anti-CD20 Monoclonal Antibodies)

Author(s) -

A. Niedermeier,

Rüdiger Eming,

Martin Pfütze,

Christine Neumann,

Christian Happel,

Kristian Reich,

Michael Hertl

Publication year - 2007

Publication title -

archives of dermatology

Language(s) - English

Resource type - Journals

eISSN - 1538-3652

pISSN - 0003-987X

DOI - 10.1001/archderm.143.2.192

Subject(s) - medicine , rituximab , epidermolysis bullosa acquisita , immunoadsorption , mucocutaneous zone , autoantibody , cd20 , immunology , monoclonal , monoclonal antibody , antibody , disease

Epidermolysis bullosa acquisita (EBA) is an autoimmune bullous disorder with mucocutaneous involvement, skin fragility, and tendency to scarring. The mechanobullous form of EBA has a chronic relapsing course and is difficult to treat. We describe herein the therapeutic response of 2 patients with recalcitrant mechanobullous EBA to combined treatment with immunoadsorption and rituximab, an anti-CD20 monoclonal antibody that induces depletion of B cells in vivo.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research